NO331721B1 - Tiofenderivater som antivirale midler for flavivirusinfeksjon, farmasoytisk preparat, anvendelse av tiofenderivater for fremstilling av medikament og fremgangsmate for fremstilling av forbindelser. - Google Patents

Tiofenderivater som antivirale midler for flavivirusinfeksjon, farmasoytisk preparat, anvendelse av tiofenderivater for fremstilling av medikament og fremgangsmate for fremstilling av forbindelser. Download PDF

Info

Publication number
NO331721B1
NO331721B1 NO20035485A NO20035485A NO331721B1 NO 331721 B1 NO331721 B1 NO 331721B1 NO 20035485 A NO20035485 A NO 20035485A NO 20035485 A NO20035485 A NO 20035485A NO 331721 B1 NO331721 B1 NO 331721B1
Authority
NO
Norway
Prior art keywords
carboxylic acid
compound
phenylthiophene
amino
thiophene
Prior art date
Application number
NO20035485A
Other languages
English (en)
Norwegian (no)
Other versions
NO20035485D0 (no
NO20035485L (no
Inventor
Chun Kong Laval Chan
Jean Bedard
Sanjoy Kumar Das
Nghe Nguyen Ba
Oswy Z Pereira
Thumkunta Jagadeeswar Reddy
M Arshad Siddiqui
Constantin Yannopoulos
Wuyi Wang
Original Assignee
Virochem Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virochem Pharma Inc filed Critical Virochem Pharma Inc
Publication of NO20035485D0 publication Critical patent/NO20035485D0/no
Publication of NO20035485L publication Critical patent/NO20035485L/no
Publication of NO331721B1 publication Critical patent/NO331721B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20035485A 2001-06-11 2003-12-10 Tiofenderivater som antivirale midler for flavivirusinfeksjon, farmasoytisk preparat, anvendelse av tiofenderivater for fremstilling av medikament og fremgangsmate for fremstilling av forbindelser. NO331721B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29673101P 2001-06-11 2001-06-11
PCT/CA2002/000876 WO2002100851A2 (en) 2001-06-11 2002-06-11 Thiophene derivatives as antiviral agents for flavivirus infection

Publications (3)

Publication Number Publication Date
NO20035485D0 NO20035485D0 (no) 2003-12-10
NO20035485L NO20035485L (no) 2004-02-06
NO331721B1 true NO331721B1 (no) 2012-03-05

Family

ID=23143308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035485A NO331721B1 (no) 2001-06-11 2003-12-10 Tiofenderivater som antivirale midler for flavivirusinfeksjon, farmasoytisk preparat, anvendelse av tiofenderivater for fremstilling av medikament og fremgangsmate for fremstilling av forbindelser.

Country Status (25)

Country Link
US (2) US6881741B2 (es)
EP (3) EP2206709A3 (es)
JP (2) JP4544857B2 (es)
KR (1) KR100900304B1 (es)
CN (2) CN100509797C (es)
AP (1) AP1753A (es)
AT (1) ATE438637T1 (es)
AU (2) AU2002344854B2 (es)
BR (1) BR0210357A (es)
CA (1) CA2450007C (es)
CY (1) CY1109497T1 (es)
CZ (1) CZ20033368A3 (es)
DE (1) DE60233227D1 (es)
DK (1) DK1401825T3 (es)
EA (1) EA007484B1 (es)
ES (1) ES2330313T3 (es)
MX (1) MXPA03011452A (es)
NO (1) NO331721B1 (es)
OA (1) OA12622A (es)
PL (2) PL208713B1 (es)
PT (1) PT1401825E (es)
SI (1) SI1401825T1 (es)
SK (1) SK288015B6 (es)
WO (1) WO2002100851A2 (es)
ZA (1) ZA200309590B (es)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
JP4544857B2 (ja) * 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
JP2005506334A (ja) * 2001-10-04 2005-03-03 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
JP2005531608A (ja) * 2002-06-06 2005-10-20 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
TW200418863A (en) * 2002-10-17 2004-10-01 Upjohn Co Novel anthelmintic and insecticidal compositions
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20040192707A1 (en) * 2002-12-10 2004-09-30 Laval Chan Chun Kong Compounds and methods for the treatment or prevention of Flavivirus infections
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
NZ540799A (en) * 2002-12-10 2008-09-26 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
ATE450498T1 (de) * 2002-12-23 2009-12-15 4Sc Ag Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP1944042A1 (en) * 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
ATE416789T1 (de) * 2003-10-27 2008-12-15 Vertex Pharma Kombinationen für die hcv-behandlung
DE10359791A1 (de) * 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
DE102005028077A1 (de) * 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
DE102004061746A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
UA89514C2 (uk) 2004-12-30 2010-02-10 Janssen Pharmaceutica Nv Похідні феніламідів 4-(бензил)-піперазин-1-карбонових кислот та споріднені сполуки як модулятори гідролази амідів жирних кислот для лікування тривоги, болю та інших станів
AU2006243245A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AU2011205048B2 (en) * 2005-05-13 2013-05-02 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
KR20080016597A (ko) * 2005-05-13 2008-02-21 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
CN101331125A (zh) * 2005-12-12 2008-12-24 健亚生物科技公司 N-(5-元杂芳香环)-酰胺基抗病毒化合物
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
TW200800969A (en) * 2005-12-22 2008-01-01 Smithkline Beecham Corp Compounds
MX2009000513A (es) * 2006-07-14 2009-03-09 Genelabs Tech Inc Agentes antivirales.
WO2008017688A1 (en) * 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
WO2008023720A1 (fr) * 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
ES2392948T3 (es) 2006-10-10 2012-12-17 Janssen Products, L.P. Intermedio para inhibidores nucleosídicos de VHC
WO2008043791A2 (en) * 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
KR20090086081A (ko) 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
ATE524465T1 (de) * 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
GB0707092D0 (en) * 2007-04-12 2007-05-23 Smithkline Beecham Corp Compounds
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
JP2010528114A (ja) * 2007-05-25 2010-08-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ
GB0712393D0 (en) * 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
US8178699B2 (en) * 2008-07-30 2012-05-15 Pfizer Inc. Modulators of CCR9 receptor and methods of use thereof
CN102256969A (zh) * 2008-08-27 2011-11-23 钙医学公司 调节胞内钙的化合物
WO2010031832A2 (en) * 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
EP2341924A4 (en) 2008-10-02 2013-01-23 David Gladstone Inst METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
US8461159B2 (en) * 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
PT2373172E (pt) 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
WO2010075376A2 (en) * 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
CA2740195A1 (en) * 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8193372B2 (en) * 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
EP2419404B1 (en) * 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
DK2455376T3 (en) * 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CN102471327A (zh) * 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
CA2771124C (en) * 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2499493A1 (en) 2009-11-14 2012-09-19 F. Hoffmann-La Roche AG Biomarkers for predicting rapid response to hcv treatment
CA2781614A1 (en) * 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
KR20120085877A (ko) 2009-12-02 2012-08-01 에프. 호프만-라 로슈 아게 Ｈｃｖ 치료에 대한 지속된 반응을 예측하기 위한 생체마커
US20130072523A1 (en) 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP3219713A1 (en) 2010-01-15 2017-09-20 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2523951B1 (en) 2010-01-15 2015-04-22 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
CA2788348A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
MX2012010919A (es) 2010-03-24 2013-02-01 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
CA2800509A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AR081691A1 (es) 2010-06-28 2012-10-10 Vertex Pharma Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
CA2806108A1 (en) * 2010-07-22 2012-01-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
MX2013004655A (es) 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
TW201307334A (zh) 2010-12-17 2013-02-16 Cocrystal Discovery Inc Ｃ型肝炎病毒聚合酶抑制劑
EP2681205B1 (en) * 2011-03-03 2016-11-16 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
JP6050763B2 (ja) * 2011-03-03 2016-12-21 デノバメド インク． 抗菌性の化合物／アジュバント化合物および方法
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
CA2840445A1 (en) 2011-07-13 2013-01-17 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
CN103917541B (zh) 2011-10-10 2016-08-17 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
CN103059042B (zh) * 2011-10-18 2015-10-07 银杏树药业(苏州)有限公司 噻吩类衍生物及其在药学中的用途
AU2012347785B2 (en) 2011-12-06 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
CN103987723B (zh) 2011-12-16 2017-03-01 弗·哈夫曼-拉罗切有限公司 Hcv ns5a 的抑制剂
AU2012357986B2 (en) 2011-12-20 2017-02-02 Riboscience Llc 4'-Azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
AU2012357940B2 (en) 2011-12-20 2017-02-16 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2817291A1 (en) 2012-02-24 2014-12-31 F. Hoffmann-La Roche AG Antiviral compounds
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9707215B2 (en) 2012-06-20 2017-07-18 Cocrystal, Discovery, Inc. Inhibitors of hepatitis C virus polymerase
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
WO2014036443A2 (en) 2012-08-31 2014-03-06 Novadrug, Llc Heterocyclyl carboxamides for treating viral diseases
KR20150109451A (ko) 2013-01-23 2015-10-01 에프. 호프만-라 로슈 아게 항바이러스성 트라이아졸 유도체
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
RU2015136256A (ru) 2013-03-05 2017-04-10 Ф. Хоффманн-Ля Рош Аг Противовирусные соединения
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
MA46490A1 (fr) 2013-05-16 2021-04-30 Riboscience Llc Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
EA201592185A1 (ru) 2013-05-16 2016-05-31 Рибосайенс Ллк 4'-азидо, 3'-дезокси-3'-фторзамещенные нуклеозидные производные
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2945681A1 (en) 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Sitagliptin tannate complex
EP3166637B1 (en) * 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
WO2016090313A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
AR112702A1 (es) 2017-09-21 2019-11-27 Riboscience Llc Derivados de nucleósidos sustituidos con 4’-fluoro-2’-metilo como inhibidores de la replicación de hcv arn
CN112074511B (zh) * 2018-03-01 2024-04-26 托马斯·黑勒戴药物研究基金会 取代的苯并二唑及其在治疗中的用途
TWI833753B (zh) 2018-05-09 2024-03-01 美商共結晶製藥公司 用於治療hcv之組合療法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
WO2021257660A1 (en) * 2020-06-16 2021-12-23 Dana-Farber Cancer Institute, Inc. Small molecule covalent activators of ucp1

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076817A (en) 1963-02-05 New j-amino-thiophene-z
DE1055077B (de) 1956-02-08 1959-04-16 Bayerische Schrauben Und Feder Telephonkabelsteckverbinder
DE1055007B (de) * 1957-08-29 1959-04-16 Dr Hans Fiesselmann Verfahren zur Herstellung von 3-Aminothiophen-2-carbonsaeureestern und den entsprechenden freien Carbonsaeuren
US3470151A (en) * 1966-05-17 1969-09-30 Beecham Group Ltd Furyl- and thienyl-penicillins and salts thereof
JPS4811691B1 (es) 1967-07-07 1973-04-14
US3823161A (en) 1970-05-07 1974-07-09 Exxon Research Engineering Co Aminothiophene derivatives
US3852293A (en) 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
AU518216B2 (en) 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
DD146952A1 (de) 1979-11-09 1981-03-11 Karl Gewald Verfahren zur herstellung von substituierten 3-amino-4-cyan-5-phenylthiophenen
JPS57116077A (en) 1981-01-12 1982-07-19 Kanebo Ltd Thieno(3,2-b)pyridinecarboxylic acid derivative
US4666502A (en) 1982-02-09 1987-05-19 Sandoz Ltd. Herbicidal N-thienyl-chloroacetamides
DE3371082D1 (de) 1982-09-09 1987-05-27 Hoffmann La Roche Thieno(2,3-e)-1,2-thiazine derivatives
GB8515207D0 (en) 1985-06-15 1985-07-17 Boots Co Plc Therapeutic agents
JPS63126884A (ja) 1986-11-17 1988-05-30 Sankyo Co Ltd オキサゾロチエノピリミジン誘導体
GB8627698D0 (en) 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DD263055A1 (de) 1987-07-28 1988-12-21 Univ Dresden Tech Verfahren zur herstellung substituierter 3-amino-5-phenyl-thiophene
DE3932052A1 (de) 1989-09-26 1991-04-04 Basf Ag Oxazol- bzw. thiazolcarbonsaeureamide
ATE127122T1 (de) 1990-06-23 1995-09-15 Basf Ag Dicarbonsäureimide als herbizide.
DE4023048A1 (de) 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JP2574085B2 (ja) 1991-10-28 1997-01-22 株式会社トクヤマ ３−アミノ−２−チオフェンカルボン酸誘導体の製造方法
FR2689129B1 (fr) 1992-03-27 1995-05-12 Atochem Elf Sa Nouveaux dérivés de l'acide 3-mercapto-2-thénoique et leurs procédés de préparation.
JPH0625221A (ja) 1992-07-10 1994-02-01 Tokuyama Soda Co Ltd ３−アミノ−２−チオフェンカルボン酸誘導体の製造方法
DE4244069A1 (de) 1992-12-24 1994-06-30 Hoechst Ag Cephalosporinsalze und Verfahren zu deren Herstellung
JPH0748360A (ja) 1993-05-31 1995-02-21 Yoshitomi Pharmaceut Ind Ltd ビフェニルテトラゾール誘導体
JPH0718360A (ja) 1993-07-07 1995-01-20 Sumitomo Light Metal Ind Ltd 耐摩耗性に優れたＴｉ−Ａｌ系金属間化合物部材及びその製造方法
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
CA2201478A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia S.A. New carboxamides with antifungal activity
US5807854A (en) 1995-08-02 1998-09-15 J. Uriah & Cia. S.A. Pyrimidone derivatives with antifungal activity
WO1998008839A1 (en) 1996-08-26 1998-03-05 Eli Lilly And Company Combinatorial process for preparing substituted thiophene libraries
JP4000608B2 (ja) 1996-11-07 2007-10-31 トヨタ自動車株式会社 水素製造充填装置および電気自動車
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
WO1998052558A1 (en) 1997-05-23 1998-11-26 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
CA2291065C (en) * 1997-05-23 2010-02-09 Bayer Corporation Raf kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
AU739385B2 (en) 1997-09-02 2001-10-11 Mitsubishi Pharma Corporation Condensed thiophene compounds and pharmaceutical use thereof
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
AU2003204708B2 (en) 1997-12-22 2006-05-25 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US20050119332A1 (en) 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6147085A (en) * 1999-04-01 2000-11-14 Neurogen Corporation Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives
US6689754B1 (en) 1998-04-10 2004-02-10 G. D. Searle & Co. Heterocyclic glycyl β-alanine derivatives
ES2188095T3 (es) 1998-04-15 2003-06-16 Pfizer Prod Inc Carboxamidas heterociclicas.
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
US6858223B2 (en) * 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
ATE253061T1 (de) * 1998-06-29 2003-11-15 Iaf Biochem Int Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
PL356984A1 (en) * 1998-08-20 2004-07-12 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents, methods and intermediates for their preparation
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
DE19903398A1 (de) * 1999-01-29 2000-08-10 Hassan Jomaa Verwendung von Thiadiazolderivaten zur prophylaktischen und therapeutischen Behandlung von Infektionen
JP2003529536A (ja) 1999-02-09 2003-10-07 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド Ｃ１ｓ介在疾患および状態の処置法、およびそれのための化合物および組成物
DE60023853T2 (de) 1999-03-12 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
WO2000055139A2 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
JP2001010957A (ja) 1999-04-28 2001-01-16 Sankyo Co Ltd 肝障害の予防または抑制剤
DE19920247A1 (de) * 1999-05-03 2000-11-16 Hassan Jomaa Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
AU7446600A (en) 1999-10-01 2001-05-10 Japan Energy Corporation Novel diarylamide derivatives and use thereof as medicines
US6620767B1 (en) * 1999-11-29 2003-09-16 Novartis Animal Health Us, Inc. Pesticidal n-heteroaryl alpha-alkoximino-carboxamides
DE10002424A1 (de) * 2000-01-20 2001-07-26 Siemens Ag Di(het)arylaminothiophen-Derivate
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2001354658A (ja) 2000-06-15 2001-12-25 Taisho Pharmaceut Co Ltd ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
PT1341757E (pt) 2000-11-08 2006-12-29 Syngenta Participations Ag Pirrolecarboxamidas e pirrolecarbotiamidas e suas utilizações agroquímicas
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US6892279B2 (en) * 2000-11-30 2005-05-10 Mosaid Technologies Incorporated Method and apparatus for accelerating retrieval of data from a memory system with cache by reducing latency
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JP2004518732A (ja) 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
EP1364212B1 (en) 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
US20040102324A1 (en) 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
JP2004538258A (ja) 2001-03-13 2004-12-24 クイーンズ　ユニバーシティ　アット　キングストン 抗癲癇誘発剤
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
JP4544857B2 (ja) * 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
JP2003073357A (ja) 2001-09-03 2003-03-12 Mitsubishi Pharma Corp アミド化合物を含有するＲｈｏキナーゼ阻害剤
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2005506334A (ja) * 2001-10-04 2005-03-03 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
US7285557B2 (en) 2001-10-15 2007-10-23 Smithkline Beecham P.L.C. Pyrimidinones as melanin concentrating hormone receptor 1
US7220777B2 (en) 2001-10-15 2007-05-22 Smithkline Beecham P.L.C. Lactam derivatives as antagonists for human 11cby receptors
TWI281916B (en) * 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
WO2003055479A1 (en) * 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
US20030220336A1 (en) 2002-04-05 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method of treating mucus hypersecretion
CA2484822A1 (en) * 2002-05-28 2003-12-04 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
CN1155679C (zh) 2002-09-20 2004-06-30 华南理工大学 含低聚噻吩骨格的液晶化合物及其制备方法
RU2005115842A (ru) 2002-10-24 2006-03-10 Мерк Патент ГмбХ (DE) Производные метиленмочевины
EP1560827B1 (en) 2002-11-01 2010-12-29 Abbott Laboratories Anti-infective agents
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US20040162285A1 (en) 2002-11-01 2004-08-19 Pratt John K. Anti-infective agents
US20050075331A1 (en) 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
US20040097492A1 (en) 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
US20040192707A1 (en) 2002-12-10 2004-09-30 Laval Chan Chun Kong Compounds and methods for the treatment or prevention of Flavivirus infections
US7402608B2 (en) 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
TW200418825A (en) * 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
AU2005228899A1 (en) 2004-03-30 2005-10-13 Novartis Vaccines And Diagnostics, Inc. Substituted thiophene derivatives as anti-cancer agents
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
KR20080016597A (ko) * 2005-05-13 2008-02-21 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법

Also Published As

Publication number Publication date
EA007484B1 (ru) 2006-10-27
JP5412370B2 (ja) 2014-02-12
EP2206709A3 (en) 2011-06-29
SI1401825T1 (sl) 2010-01-29
WO2002100851A2 (en) 2002-12-19
PT1401825E (pt) 2009-10-23
US6881741B2 (en) 2005-04-19
EP2363396A1 (en) 2011-09-07
WO2002100851A3 (en) 2003-02-27
CN1602308A (zh) 2005-03-30
JP2010209095A (ja) 2010-09-24
ATE438637T1 (de) 2009-08-15
OA12622A (en) 2006-06-12
NO20035485D0 (no) 2003-12-10
EP2206709A2 (en) 2010-07-14
EP1401825A2 (en) 2004-03-31
CA2450007C (en) 2012-04-17
AU2002344854B2 (en) 2008-11-06
ZA200309590B (en) 2004-05-12
AU2009200430A1 (en) 2009-02-26
AU2009200430B2 (en) 2012-02-09
SK288015B6 (sk) 2012-11-05
PL367080A1 (en) 2005-02-21
CZ20033368A3 (en) 2004-04-14
JP2005500288A (ja) 2005-01-06
US7985769B2 (en) 2011-07-26
CY1109497T1 (el) 2014-08-13
CN101624391A (zh) 2010-01-13
CA2450007A1 (en) 2002-12-19
PL395097A1 (pl) 2011-10-10
NO20035485L (no) 2004-02-06
EP1401825B1 (en) 2009-08-05
DK1401825T3 (da) 2009-11-09
BR0210357A (pt) 2004-06-29
SK15202003A3 (sk) 2004-07-07
EA200400022A1 (ru) 2004-06-24
ES2330313T3 (es) 2009-12-09
US20060142347A1 (en) 2006-06-29
US20040116509A1 (en) 2004-06-17
AP2003002932A0 (en) 2003-12-31
KR100900304B1 (ko) 2009-06-02
JP4544857B2 (ja) 2010-09-15
PL208713B1 (pl) 2011-05-31
KR20040030671A (ko) 2004-04-09
DE60233227D1 (de) 2009-09-17
CN100509797C (zh) 2009-07-08
AP1753A (en) 2007-07-18
MXPA03011452A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
NO331721B1 (no) Tiofenderivater som antivirale midler for flavivirusinfeksjon, farmasoytisk preparat, anvendelse av tiofenderivater for fremstilling av medikament og fremgangsmate for fremstilling av forbindelser.
AU2002344854A1 (en) Thiophene derivatives as antiviral agents for flavivirus infection
JP4926403B2 (ja) フラビウイルス感染の処置もしくは予防のための化合物および方法
US8829030B2 (en) Compounds and methods for the treatment or prevention of Flavivirus infections
BRPI0610283A2 (pt) composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
BG107633A (bg) Фармацевтично активни сулфонамидни производни съдържащи едновременно липофилни и йонизиращи се части като инхибитори на протеинови jun - кинази
US8329924B2 (en) Compounds and methods for the treatment or prevention of Flavivirus infections
AU2012202716A1 (en) Thiophene derivatives as antiviral agents for flavivirus infection

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees